• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by PepGen Inc.

    3/11/26 4:06:24 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PEPG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    PepGen Inc.

    (Name of Issuer)


    Common stock, par value $0.0001 per share

    (Title of Class of Securities)




    03/04/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Commodore Capital LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,544,101.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,544,101.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,544,101.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Commodore Capital Master LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,544,101.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,544,101.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,544,101.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Robert Egen Atkinson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,544,101.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,544,101.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,544,101.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP Number(s):


    1Names of Reporting Persons

    Michael Kramarz
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,544,101.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,544,101.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,544,101.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PepGen Inc.
    (b)Address of issuer's principal executive offices:

    321 Harrison Avenue, 8th Floor, Boston, MASSACHUSETTS, 02118.
    Item 2. 
    (a)Name of person filing:

    Commodore Capital LP Commodore Capital Master LP Robert Egen Atkinson Michael Kramarz Each a "Filer."
    (b)Address or principal business office or, if none, residence:

    The address for Commodore Capital LP, Robert Egen Atkinson, and Michael Kramarz is 444 Madison Avenue, Floor 35, New York, NY 10022. The address for Commodore Capital Master LP is c/o Maples Corporate Services Limited, Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands.
    (c)Citizenship:

    See Item 4 of the cover page for each Filer.
    (d)Title of class of securities:

    Common stock, par value $0.0001 per share
    (e)CUSIP No.:

    713317105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Item 9 of the cover page for each Filer. This report on Schedule 13G is being filed by Commodore Capital LP (the "Firm"), Commodore Capital Master LP ("Commodore Master"), Michael Kramarz, and Robert Egen Atkinson. The Firm is the investment manager to Commodore Master. As of March 4, 2026, the Firm may be deemed to beneficially own an aggregate of 3,544,101 shares of Common stock, par value $0.0001 per share (the "Common Stock"), of PepGen Inc. (the "Issuer"). The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 69,115,292 Common Stock reported as issued and outstanding as of February 26, 2026 in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2026.
    (b)Percent of class:

    See Item 11 of the cover page for each Filer.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 of the cover page for each Filer.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 of the cover page for each Filer.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 of the cover page for each Filer.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 of the cover page for each Filer.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Commodore Capital LP
     
    Signature:Michael Kramarz
    Name/Title:Managing Partner
    Date:03/11/2026
     
    Commodore Capital Master LP
     
    Signature:Michael Kramarz
    Name/Title:Authorized Signatory
    Date:03/11/2026
     
    Robert Egen Atkinson
     
    Signature:Robert Egen Atkinson
    Name/Title:Authorized Signatory
    Date:03/11/2026
     
    Michael Kramarz
     
    Signature:Michael Kramarz
    Name/Title:Authorized Signatory
    Date:03/11/2026
    Exhibit Information

    Exhibit 1: Joint Filing Agreement

    Get the next $PEPG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PEPG

    DatePrice TargetRatingAnalyst
    9/9/2025$6.00Buy
    Guggenheim
    12/16/2024$3.00Neutral → Underperform
    BofA Securities
    7/31/2024$12.00Buy → Neutral
    BofA Securities
    12/21/2022$26.00Buy
    H.C. Wainwright
    More analyst ratings

    $PEPG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Head of R&D Streck Paul sold $11,709 worth of shares (1,879 units at $6.23), decreasing direct ownership by 2% to 76,226 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    3/6/26 4:14:09 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Donnelly Noel sold $12,988 worth of shares (2,084 units at $6.23), decreasing direct ownership by 2% to 111,603 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    3/6/26 4:12:08 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Mcarthur James G sold $32,876 worth of shares (5,275 units at $6.23), decreasing direct ownership by 2% to 296,326 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    3/6/26 4:09:30 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PepGen Announces Regulatory Updates on FREEDOM2

    - U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and New Zealand and dosing of the 10 mg/kg cohort continues in the UK and Canada - - PepGen reiterates guidance for reporting data from the FREEDOM2 5 mg/kg cohort in Q1 2026 and from the 10 mg/kg cohort in 2H 2026 - PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies to treat severe neuromuscular and neurological diseases, today announced regulatory updates related to the FREEDOM2 trial. The U.S. Food and Drug Administrati

    3/4/26 4:03:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen to Participate in the Leerink Global Healthcare Conference

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 p.m. ET in Miami, Florida. A webcast of the event will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com/. A replay of the webcast will be available on the PepGen website for 90 days following the presentatio

    3/3/26 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen's 2024 Inducement Plan as a material inducement to employment to its newly appointed Chief Business and Legal Officer, Joseph Vittiglio. On December 8, 2025, Mr. Vittiglio received a non-qualified stock option grant to purchase 160,000 shares of PepGen's common stock, par value $0.0001 per share, with an exercise price of $5.59 per share, the closing price of PepGen's common stock as reported by The Nasdaq Global S

    12/9/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by PepGen Inc.

    SCHEDULE 13G - PepGen Inc. (0001835597) (Subject)

    3/11/26 4:06:24 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PepGen Inc. (0001835597) (Filer)

    3/4/26 5:02:16 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by PepGen Inc.

    S-8 - PepGen Inc. (0001835597) (Filer)

    3/4/26 4:20:26 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on PepGen with a new price target

    Guggenheim initiated coverage of PepGen with a rating of Buy and set a new price target of $6.00

    9/9/25 7:59:59 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded PepGen from Neutral to Underperform and set a new price target of $3.00

    12/16/24 12:07:01 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00

    7/31/24 11:28:59 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Former 10% Owner Oxford Science Enterprises Plc bought $640,000 worth of shares (200,000 units at $3.20), increasing direct ownership by 4% to 4,955,388 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    10/1/25 1:07:57 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $30,000,000 worth of shares (9,375,000 units at $3.20) (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    9/30/25 4:35:57 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Head of R&D Streck Paul bought $10,393 worth of shares (8,375 units at $1.24), increasing direct ownership by 43% to 27,805 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    6/2/25 5:03:19 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Leadership Updates

    Live Leadership Updates

    View All

    PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Joseph Vittiglio, Esq., as Chief Business and Legal Officer. Mr. Vittiglio brings more than two decades of executive leadership experience across legal, compliance, corporate development, and corporate governance within public biotechnology companies. "Joe is a deeply experienced legal and business leader with a proven track record guiding companies through complex transactions, regulatory milestones, financings, product launches, and stra

    12/8/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

    5/20/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Announces Appointment of Two New Directors to its Board

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company. "We are thrilled to welcome Lisa and Mitch to our Board of Directors," said James McArthur, PhD, President and CEO of PepGen. "Lisa's proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies

    3/31/25 4:05:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PepGen Inc.

    SC 13G/A - PepGen Inc. (0001835597) (Subject)

    11/14/24 4:31:29 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by PepGen Inc.

    SC 13G - PepGen Inc. (0001835597) (Subject)

    11/14/24 11:10:10 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PepGen Inc.

    SC 13G/A - PepGen Inc. (0001835597) (Subject)

    11/12/24 8:57:04 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Financials

    Live finance-specific insights

    View All

    PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

    – Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today at 8:00 a.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). "These results far exceeded our expectations for splicing correctio

    2/24/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

    – PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation

    7/30/24 4:02:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call

    BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived

    3/16/23 8:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care